Search Within

Anthony R Mato

Formats
  1. Meeting Abstract (135)
  2. Journal Article (62)
  3. Review (16)
  4. Research Letter (10)
  5. Editorial (7)
  6. Guidelines (3)
  7. Book Section (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (235)
  2. Center for Hematologic Malignancies (235)
  3. Department of Medicine (235)
  4. Hematologic Malignancies, Division of (235)
  5. Lymphoma (47)
  6. GME, Medicine (32)

More Groups

People
  1. Lindsey Roeker (94)
  2. Andrew Zelenetz (33)
  3. Meghan Thompson (30)
  4. Omar Abdel-Wahab (19)
  5. Maria Palomba (18)
  6. Colleen Dorsey (14)

More People

Years
  1. 2025 (3)
  2. 2024 (2)
  3. 2023 (22)
  4. 2022 (49)
  5. 2021 (39)
  6. 2020 (52)

More Years

Publications
  1. Blood (82)
  2. Journal of Clinical Oncology (18)
  3. Clinical Lymphoma, Myeloma and Leukemia (16)
  4. Leukemia and Lymphoma (16)
  5. British Journal of Haematology (15)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (94)
  2. American Society of Clinical Oncology (19)
  3. Elsevier Inc. (18)
  4. Taylor & Francis Group (18)
  5. John Wiley & Sons (16)
  6. American Association for Cancer Research (10)

More Publishers

Results (235)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characteristics and outcomes of ibrutinib-associated musculoskeletal toxities in CLL patients
    Meeting Abstract

    Rhodes, J.; Mato, A. R.; Winchell, N.; Kennard, K.; Gerson, J. N.; Landsburg, D. J.; Nasta, S. D.; Svoboda, J.; Schuster, S. J.
    Blood (2018)

    Fulltext@MSK | Save
  • Real-world treatment patterns among a contemporary cohort of commercially insured mantle cell lymphoma patients in the United States
    Meeting Abstract

    Roeker, L. E.; Kabadi, S.; Burudpakdee, C.; Near, A.; Wada, K.; Mato, A. R.
    Blood (2018)

    Fulltext@MSK | Save
  • Comparison of costs and health care resource utilization (HRU) in chronic lymphocytic leukemia (CLL) patients treated with venetoclax (VEN) or chemotherapy (CT)/chemoimmunotherapy (CIT)
    Meeting Abstract

    Nabhan, C.; Mato, A. R.; Kish, J. K.; Nero, D.
    Blood (2018)

    Fulltext@MSK | Save
  • Cost-effectiveness comparison between ibrutinib, chemotherapy, and chemoimmunotherapy in front-line treatment of chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Nabhan, C.; Nero, D.; Lee, C. H.; Kish, J. K.; Mato, A. R.
    Blood (2018)

    Fulltext@MSK | Save
  • Venetoclax as monotherapy or in combination: Patterns of use and predictors of outcomes in an international multicenter study of CLL patients
    Meeting Abstract

    Mato, A. R.; Roeker, L. E.; Eyre, T. A.; Nabhan, C.; Lamanna, N.; Hill, B. T.; Brander, D. M.; Barr, P.; Lansigan, F.; Cheson, B.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Prognostic testing and treatment approaches in patients with chronic lymphocytic leukemia: Clinical experience from an interim analysis of the informCLL (TM) real-world registry
    Meeting Abstract

    Mato, A. R.; Barrientos, J. C.; Brander, D. M.; Pagel, J. M.; Gutierrez, M.; Kadish, K.; Tomlinson, B.; Ghosh, N.; Giafis, N.; Ipe, D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes of patients with CLL treated with chemoimmuno- and novel agent-based therapy: A multicenter study
    Meeting Abstract

    Mato, A. R.; Yazdy, M. S.; Hill, B. T.; Shadman, M.; Tuncer, H.; Winter, A. M.; Kennard, K.; Allan, J. N.; Ujjani, C. S.; Brander, D. M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase I study of first-in-class oral triplet therapy DTRM-555 in relapsed/refractory lymphoma patients through fixed-dose combination and synthetic lethality
    Meeting Abstract

    Huntington, S. F.; Schuster, S. J.; He, W.; Shen, T.; Walker, H.; Leary, L.; Boyhen, K.; Gill, J.; Chatburn, E. T.; Kennard, K.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Treatment patterns, adverse events, and economic burden in a privately insured population of newly diagnosed patients with chronic lymphocytic leukemia in the United States
    Meeting Abstract

    Kabadi, S.; Goyal, R. K.; Nagar, S. P.; Kaye, J. A.; Davis, K. L.; Mato, A. R.
    Blood (2018)

    Fulltext@MSK | Save
  • Outcomes of ibrutinib therapy given after prior venetoclax therapy in ibrutinib-naïve patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Brown, J. R.; Davids, M. S.; Chang, J. L.; Ma, S.; Biondo, J.; Mobasher, M.; Mun, Y.; Mato, A. R.
    Blood (2018)

    Fulltext@MSK | Save